Warning Letter: New Sponsor, Same Violative Promotional Practices For Insomnia Drug Doral
Executive Summary
An OPDP warning letter hits Galt Pharmaceuticals for misbranding its insomnia drug Doral with similar to concerns to those outlined in a 2014 untitled letter to the then-sponsor Sciecure.